Literature DB >> 23567400

The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease.

Paul B Rosenberg1, Michelle M Mielke, Brian S Appleby, Esther S Oh, Yonas E Geda, Constantine G Lyketsos.   

Abstract

OBJECTIVES: Individuals with mild cognitive impairment (MCI) are at high risk of developing dementia and/or Alzheimer disease (AD). Among persons with MCI, depression and anxiety have been associated with an increased risk of incident dementia. We examined whether neuropsychiatric symptoms in MCI increased the risk of incident dementia (all-cause) and incident AD.
DESIGN: Longitudinal cohort study followed annually (median: 1.58 years).
SETTING: National Alzheimer's Coordinating Center database combining clinical data from 29 Alzheimer's Disease Centers. PARTICIPANTS: A total of 1,821 participants with MCI. MEASUREMENTS: 1) Progression to dementia (all-cause) or AD, 2) Neuropsychiatric Inventory Questionnaire (NPI-Q), 3) Geriatric Depression Scale (GDS), 4) Clinical Dementia Rating Global Score and Sum of Boxes, and 5) Mini-Mental State Examination (MMSE). The association of covariates with risk of incident dementia or AD was evaluated with hazard ratios (HR) determined by Cox proportional-hazards models adjusted for age, ethnicity, Clinical Dementia Rating Global Score and Sum of Boxes, and MMSE.
RESULTS: A total of 527 participants (28.9%) progressed to dementia and 454 (24.9%) to AD. Baseline GDS > 0 was associated with an increased risk of incident dementia (HR: 1.47, 95% CI: 1.17-1.84) and AD (HR: 1.45, 95% CI: 1.14-1.83). Baseline NPI > 0 was associated with an increased risk of incident dementia (HR: 1.37, 95% CI: 1.12-1.66) and AD (HR: 1.35, 95% CI: 1.09-1.66).
CONCLUSIONS: Neuropsychiatric symptoms in MCI are associated with significantly an increased risk of incident dementia and AD. Neuropsychiatric symptoms may be among the earliest symptoms of preclinical stages of AD and targeting them therapeutically might delay transition to dementia.
Copyright © 2013 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23567400      PMCID: PMC3428504          DOI: 10.1016/j.jagp.2013.01.006

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  41 in total

1.  Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease.

Authors:  Aneta Grudzien; Pamela Shaw; Sandra Weintraub; Eileen Bigio; Deborah C Mash; M Marsel Mesulam
Journal:  Neurobiol Aging       Date:  2006-03-29       Impact factor: 4.673

2.  Influence of premorbid IQ and education on progression of Alzheimer's disease.

Authors:  V N Pavlik; R S Doody; P J Massman; W Chan
Journal:  Dement Geriatr Cogn Disord       Date:  2006-09-05       Impact factor: 2.959

3.  Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; Mark F Desrosiers; William R Markesbery
Journal:  Neurobiol Aging       Date:  2005-03       Impact factor: 4.673

4.  The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers.

Authors:  John C Morris; Sandra Weintraub; Helena C Chui; Jeffrey Cummings; Charles Decarli; Steven Ferris; Norman L Foster; Douglas Galasko; Neill Graff-Radford; Elaine R Peskind; Duane Beekly; Erin M Ramos; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Oct-Dec       Impact factor: 2.703

5.  Conversion to dementia from mild cognitive disorder: the Cache County Study.

Authors:  J T Tschanz; K A Welsh-Bohmer; C G Lyketsos; C Corcoran; R C Green; K Hayden; M C Norton; P P Zandi; L Toone; N A West; J C S Breitner
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

6.  Predictors of progression from mild cognitive impairment to Alzheimer disease.

Authors:  K Palmer; A K Berger; R Monastero; B Winblad; L Bäckman; L Fratiglioni
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

Review 7.  The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set.

Authors:  Duane L Beekly; Erin M Ramos; William W Lee; Woodrow D Deitrich; Mary E Jacka; Joylee Wu; Janene L Hubbard; Thomas D Koepsell; John C Morris; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Jul-Sep       Impact factor: 2.703

8.  Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease.

Authors:  Edmond Teng; Po H Lu; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2007-08-14       Impact factor: 2.959

9.  Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study.

Authors:  Martin Steinberg; Huibo Shao; Peter Zandi; Constantine G Lyketsos; Kathleen A Welsh-Bohmer; Maria C Norton; John C S Breitner; David C Steffens; Joann T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2008-02       Impact factor: 3.485

10.  Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment.

Authors:  Bradford C Dickerson; Reisa A Sperling; Bradley T Hyman; Marilyn S Albert; Deborah Blacker
Journal:  Arch Gen Psychiatry       Date:  2007-12
View more
  92 in total

1.  Clinicopathological correlates of depression in early Alzheimer's disease in the NACC.

Authors:  Sarah T McCutcheon; Dingfen Han; Juan Troncoso; Vassilis E Koliatsos; Marilyn Albert; Constantine G Lyketsos; Jeannie-Marie S Leoutsakos
Journal:  Int J Geriatr Psychiatry       Date:  2016-02-14       Impact factor: 3.485

2.  Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Constantine G Lyketsos; Gwenn S Smith
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Skin Conduction Levels Differentiate Frontotemporal Dementia From Alzheimer's Disease.

Authors:  Mario F Mendez; Sylvia S Fong; Mark M Ashla; Elvira E Jimenez; Andrew R Carr
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2018-04-06       Impact factor: 2.198

4.  Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment.

Authors:  Zahinoor Ismail; Eric E Smith; Yonas Geda; David Sultzer; Henry Brodaty; Gwenn Smith; Luis Agüera-Ortiz; Rob Sweet; David Miller; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2015-06-18       Impact factor: 21.566

5.  A Novel 1,4-Dihydropyridine Derivative Improves Spatial Learning and Memory and Modifies Brain Protein Expression in Wild Type and Transgenic APPSweDI Mice.

Authors:  Baiba Jansone; Inga Kadish; Thomas van Groen; Ulrika Beitnere; Doyle Ray Moore; Aiva Plotniece; Karlis Pajuste; Vija Klusa
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

Review 6.  Diagnosis and treatment of depression and cognitive impairment in late life.

Authors:  Sarah Shizuko Morimoto; Dora Kanellopoulos; Kevin J Manning; George S Alexopoulos
Journal:  Ann N Y Acad Sci       Date:  2015-02-05       Impact factor: 5.691

7.  Detecting and Managing Neuropsychiatric Symptoms in Dementia.

Authors:  Andrea Iaboni; Mark J Rapoport
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

8.  Symptom Clusters of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Comparative Risks of Dementia: A Cohort Study of 8530 Older Persons.

Authors:  Tau Ming Liew
Journal:  J Am Med Dir Assoc       Date:  2019-03-26       Impact factor: 4.669

9.  The default mode network may be the key substrate of depressive symptom-related cognitive changes.

Authors:  Donald R Royall; Raymond F Palmer; Eric D Vidoni; Robyn A Honea
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  The association of depression, cognitive impairment without dementia, and dementia with risk of ischemic stroke: a cohort study.

Authors:  Dimitry S Davydow; Deborah A Levine; Kara Zivin; Wayne J Katon; Kenneth M Langa
Journal:  Psychosom Med       Date:  2015 Feb-Mar       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.